
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated a notable improvement in financial performance, with a year-over-year operating margin increase of 180 basis points, driven by gross margin expansion and effective SG&A management, despite SG&A expenses rising to 39.5% of sales. The company reported a mid-single-digit revenue growth of 6.7% for 2024 and expects ongoing momentum in 2025, particularly with projected organic growth in its Cardiopulmonary segment of 7.0-8.0% due to successful product launches and market share gains. Additionally, LivaNova's capacity constraints for oxygenators are being addressed, with plans for a 10-15% capacity increase expected in 2025, which should further support revenue advancements as the demand from elective procedures rises post-pandemic.
Bears say
LivaNova's financial outlook is negatively impacted by a notable slowdown in organic revenue growth, which decreased to 7% in 4Q24 from 12% in the previous quarter, alongside a weak performance in the neuromodulation segment, which grew only 1.0% against consensus expectations. The company faces operational challenges, particularly in the international neuromodulation business, compounded by assumptions of continued headwinds in its Neuromodulation and Cardiovascular divisions, which may lead to overall revenue growth slowing to the low-single digits. Additionally, LivaNova's 2025 revenue guidance midpoint was slightly below consensus, indicating potential difficulties in meeting market expectations despite a comparatively favorable EPS guidance.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares